Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.72 |
| ▸ | HTR2A | P28223 | 14/20 | 0.67 |
| ▸ | HTR2C | P28335 | 9/20 | 0.67 |
| ▸ | HTR2B | P41595 | 7/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | HTR1B | P28222 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24163642 | 1.00 | TAAR1 (0.72) | TAAR1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL21240834 | 0.91 | TAAR1 (0.83) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL26064982 | 0.90 | TAAR1 (0.69) | TAAR1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL29364056 | 0.87 | TAAR1 (0.77) | TAAR1HTR2AHTR2C | |
| SCHEMBL1253319 | 0.87 | TAAR1 (0.77) | TAAR1HTR2AHTR2C | |
| SCHEMBL24163278 | 0.87 | HTR2A (0.57) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL27001997 | 0.86 | HTR2A (0.71) | TAAR1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL1047458 | 0.86 | TAAR1 (0.69) | TAAR1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL29473870 | 0.86 | TAAR1 (0.69) | TAAR1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL27001990 | 0.85 | HTR2A (0.69) | TAAR1HTR2AHTR2CHTR2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. | 2024-10-10 | — | — | US | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023283386-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. (US) | 2023-01-12 | — | — | WO | claimed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250353808-A1 | 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES | 2A BIOSCIENCES, INC. | 2025-11-20 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4583858-A1 | COMBINATIONS COMPRISING PSYCHEDELICS FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC AND NEUROLOGIC DISORDERS | Hadasit Medical Research Services&Development Ltd. (IL) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025137730-A1 | N-SUBSTITUTED TRYPTAMINES AND N-SUBSTITUTED LYSERGAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025099725-A1 | CONJUGATES AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2025-05-15 | — | — | WO | disclosed |
| US-20240294460-A1 | DEUTERATED ANALOGS AND DERIVATIVES OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE AND USES THEREOF | TERRAN BIOSCIENCES INC. | 2024-09-05 | — | — | US | disclosed |
| EP-4387952-A1 | DEUTERATED ANALOGS AND DERIVATIVES OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE AND USES THEREOF | Terran Biosciences Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024052895-A1 | COMBINATIONS COMPRISING PSYCHEDELICS FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC AND NEUROLOGIC DISORDERS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD (IL) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024020572-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PTSD | NEW YORK STEM CELL FOUNDATION, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024006226-A1 | N-SUBSTITUTED PHENYLALKYLAMINES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023023351-A1 | DEUTERATED ANALOGS AND DERIVATIVES OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023283386-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | BDNF, NTRK2, GRIN2A | TAAR1 138/4885HTR2A 33/4885HTR2C 55/4885 |
| US-20250353808-A1 | 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES | HTR5A, PNMT, HTR6 | TAAR1 98/4885HTR2A 8/4885HTR2C 7/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | TAAR1 79/4885HTR2A 14/4885HTR2C 42/4885 |
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | HTR6, HTR4, CNR1 | TAAR1 22/4885HTR2A 6/4885HTR2C 11/4885 |
| US-20240294460-A1 | DEUTERATED ANALOGS AND DERIVATIVES OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE AND USES THEREOF | DBH, PNMT, BRD4 | TAAR1 399/4885HTR2A 26/4885HTR2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.